Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBT Margin (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed EBT Margin for 6 consecutive years, with 6.49% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 2445.0% year-over-year to 6.49%, compared with a TTM value of 14.81% through Dec 2025, down 1197.0%, and an annual FY2025 reading of 14.81%, down 1197.0% over the prior year.
  • EBT Margin was 6.49% for Q4 2025 at Cytek Biosciences, up from 14.86% in the prior quarter.
  • Across five years, EBT Margin topped out at 17.96% in Q4 2024 and bottomed at 27.18% in Q1 2025.
  • Average EBT Margin over 5 years is 5.06%, with a median of 4.99% recorded in 2025.
  • The sharpest move saw EBT Margin surged 1367bps in 2021, then plummeted -2445bps in 2025.
  • Year by year, EBT Margin stood at 1.14% in 2021, then skyrocketed by 646bps to 8.51% in 2022, then decreased by -17bps to 7.06% in 2023, then soared by 154bps to 17.96% in 2024, then crashed by -136bps to 6.49% in 2025.
  • Business Quant data shows EBT Margin for CTKB at 6.49% in Q4 2025, 14.86% in Q3 2025, and 14.86% in Q2 2025.